Understanding polypharmacy in people with type 2 diabetes

  • Research type

    Research Study

  • Full title

    Understanding polypharmacy in people with type 2 diabetes: A qualitative study and discrete choice experiment

  • IRAS ID

    346943

  • Contact name

    David McAllister

  • Contact email

    david.mcallister@glasgow.ac.uk

  • Sponsor organisation

    NHS GG&C Research and Innovation (R&I)

  • Duration of Study in the UK

    3 years, 10 months, 25 days

  • Research summary

    Many people with type 2 diabetes are prescribed multiple medications. This includes medications for the management of diabetes, to manage risk factors linked to diabetes, and for other conditions. The use of multiple medications (typically 5 or more) is referred to as polypharmacy. Polypharmacy can be an appropriate response to managing long-term health conditions, particularly when individuals have multiple long-term conditions. However, polypharmacy can also have potentially negative implications for individuals. These include the burden of taking multiple medications, the risk of side effects of interactions, and the impact of these factors on quality of life.

    This project seeks to understand the experience of people living with type 2 diabetes and who are taking multiple medications, and their views on the subject of deprescribing (reducing or stopping medications). We will also explore the views and experiences of healthcare professionals involved in the care of people with type 2 diabetes.

    Our aims are:

    To understand the lived experience of people with type 2 diabetes who are taking multiple medications (polypharmacy), including the positive and negative aspects of multiple medications, through qualitative interviews.

    Understand the attitudes and experience of people with type 2 diabetes to deprescribing of medications (the stopping or reduction of medication).

    Understand the attitudes and experience of healthcare professionals involved in care for people with type 2 diabetes in terms of polypharmacy and deprescribing.

    To identify what attributes of polypharmacy people with type 2 diabetes value most and what they find most burdensome, assessed through a discrete choice experiment survey.

  • REC name

    East of England - Cambridge South Research Ethics Committee

  • REC reference

    25/EE/0049

  • Date of REC Opinion

    20 Mar 2025

  • REC opinion

    Further Information Favourable Opinion